Scancell Holdings Plc First Collaboration Agreement for AvidiMab (1118L)
04 Settembre 2019 - 8:00AM
UK Regulatory
TIDMSCLP
RNS Number : 1118L
Scancell Holdings Plc
04 September 2019
4 September 2019
Scancell Holdings plc
("Scancell" or the "Company")
Scancell signs first collaboration agreement for its new
platform technology, AvidiMab(TM), with leading antibody technology
company
Platform to potentially increase the potency of any therapeutic
monoclonal antibody
Scancell, the developer of novel immunotherapies for the
treatment of cancer, is pleased to announce that it has signed its
first collaboration and non-exclusive research agreement with a
leading antibody technology company to assess its pipeline of
monoclonal antibodies (mAbs) targeting tumour-associated glycans
(TaGs) that have been enhanced with its new proprietary
AvidiMab(TM) technology.
As previously announced over the last year, Scancell has been
building its pipeline of mAbs as potential novel target cancer
treatments. Most mAbs for the treatment of cancer target proteins
on the cancer cell surface and subsequently mediate an immune
response to eliminate that cell. However, there remains an unmet
need for new and improved therapeutic targets, as well as improved
approaches to mediate cell killing. All cells are covered by a
dense layer of sugar structures, called glycans, which change when
a normal cell turns into a cancer cell. TaGs are glycan motifs that
are associated with tumour malignancies and these can be targeted
by antibodies. Scancell's development pipeline includes mAbs
against specific TaGs with superior affinity and selectivity
profiles, that have now been further engineered using the Company's
AvidiMab(TM) technology; this confers the Scancell anti-TaG mAbs
with the ability to directly kill tumour cells.
AvidiMab(TM) has broad potential to increase the avidity or
potency of any therapeutic monoclonal antibody including those
being developed for autoimmune diseases, as well as cancer. A
patent application has been filed that seeks broad protection for
the AvidiMab(TM) technology. This is Scancell's third proprietary
platform technology, after ImmunoBody(R) and Moditope(R) , in the
field of immunotherapy.
Under the terms of the collaboration and research agreement,
Scancell and its partner will evaluate the potential of anti-TaG
mAbs, enhanced with AvidiMab(TM), in various formats including,
antibody drug conjugates, bispecific antibodies, as well as
stand-alone antibody products.
Dr Cliff Holloway, Chief Executive Officer, Scancell,
commented:
"We are pleased to be able to report significant progress on our
monoclonal antibody pipeline, having only licensed the technology
into the company just over a year ago from the University of
Nottingham. Our first collaboration and evaluation agreement with
one of the major players in the antibody development field is a
significant achievement in such a short period of time and we
believe our novel AvidiMab(TM) enhanced cell killing platform has
broad partnering potential."
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014 (MAR).
For Further Information:
Scancell Holdings plc
Dr John Chiplin, Chairman +44 (0) 20 3727 1000
Dr Cliff Holloway, CEO
Panmure Gordon (UK) Limited
(Nominated Adviser and Corporate
broker)
Freddy Crossley/Emma Earl +44 (0) 20 7886 2500
FTI Consulting
Simon Conway/Natalie Garland-Collins +44 (0) 20 3727 1000
About Scancell
Scancell is developing novel immunotherapies for the treatment
of cancer based on its ImmunoBody(R) and Moditope(R) technology
platforms.
ImmunoBody(R) vaccines target dendritic cells and stimulate both
parts of the cellular immune system. They have the potential to be
used as monotherapy or in combination with checkpoint inhibitors
and other agents. This platform has the potential to enhance tumour
destruction, prevent disease recurrence and extend survival.
-- SCIB1, the lead programme, is being developed for the
treatment of melanoma. A phase 1/2 clinical trial has so far
successfully demonstrated survival data of more than five
years.
-- SCIB2 is being developed for the treatment of non-small cell
lung cancer and other solid tumours. Scancell has entered into a
clinical development partnership with Cancer Research UK (CRUK) for
SCIB2.
Moditope(R) represents a completely new class of potent and
selective immunotherapy agents based on stress-induced
post-translational modifications (siPTM). It stimulates the
production of killer CD4 T cells which overcome the immune
suppression induced by tumours, allowing activated T cells to seek
out and kill tumour cells that would otherwise be hidden from the
immune system. Moditope(R) alone, or in combination with other
agents, has the potential to treat a wide variety of cancers.
-- Modi-1 is being developed for the treatment of solid tumours
including triple negative breast cancer, ovarian cancer and head
and neck cancer.
For further details, please see our website:
www.scancell.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRQXLFBKKFZBBE
(END) Dow Jones Newswires
September 04, 2019 02:00 ET (06:00 GMT)
Grafico Azioni Scancell (LSE:SCLP)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Scancell (LSE:SCLP)
Storico
Da Apr 2023 a Apr 2024